The inaugural CHINATRIALS+US Summit launches amidst the recent boom of innovative Chinese biotech startups and recent CFDA reforms that enable international biopharmas to more easily import their drugs to China.
The Summit will bring together 100+ clinical development leaders from Chinese innovative biotechs interested in launching clinical trials in the US and US biotechs interested in entering the China market.
The discussion will focus on developing an optimal global development strategy and the key considerations these companies must keep in mind when looking to launch development in the US and China markets. We hope the synergies of bringing these two important groups together will introduce new opportunities for partnerships and collaborations for parallel drug development in the US and China.
Now in its 12th year, the annual CHINATRIALS Summit has established itself as the must-attend industry-focused event for global clinical development executives interested in China development.
CHINATRIALS brings together 400+ senior clinical development executives from multinational biopharmaceutical companies and domestic pharmaceutical and new start-up biotechs.
The Summit covers a wide range of important topics for the Chinese market including regulatory policy, clinical strategy development, clinical trial design, registering imported drugs, and more. It is the only event you need to attend this year to stay updated on the scientific AND business-sides of China’s fast-moving clinical development industry.